Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

152.65 +1.52 (+1.01%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Study Shows 186 Banks Are On The Brink Of Failure
The Fed has done it again: raised their interest rates for the 9th time on March 22, 2023, by 25 basis points. This brings the fed fund rate to 4.75%-5%. However, this move sent mixed signals. 
Via Talk Markets
New Regional Director for EMEA to Drive Next Stage of Growth Across the Region for Jeron Nurse Call Systems
NILES, Ill. - March 24, 2023 - PRLog -- Jeron Electronic Systems, Inc. announced today that Dr. Ahmed Adel MBA-MDS has joined the Jeron sales team as the Regional Director for the EMEA. In this newly... 
Via PRLog
Topics Economy
Exposures Supply Chain
Looking At Johnson & Johnson's Recent Unusual Options Activity
 
Via Benzinga
Ready to Buy the Dip? Johnson & Johnson Stock Is a Smart Buy
Close to its 52-week low, this healthcare stalwart remains a good purchase. 
Via The Motley Fool
Looking Into Johnson & Johnson's Recent Short Interest
 
Via Benzinga
Binance Suspends Trading, European Bank Trouble, Twitter To Remove Legacy Verified Checkmarks: Today's Top Stories
Reuters 
Via Benzinga
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India, Makes Way For Domestic Generic Players
 
Via Benzinga
Have $1,000? 2 Smart Stocks to Buy This Month
The market is still giving investors great opportunities to buy exceptional companies. 
Via The Motley Fool
3 Safe Dow Dividend Stocks to Buy Now
These companies combine regimented growth with income for a balanced overall value. 
Via The Motley Fool
Think the Bear Market Is Over? Here's How to Invest $5,000
The worst might be in the rearview mirror as far as the latest bear market is concerned. 
Via The Motley Fool
Johnson & Johnson Unusual Options Activity
 
Via Benzinga
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
 
Via Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga 
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? 
Via News Direct
Exposures Product Safety
2 Stocks That Should Be Better Buys After Their Spinoffs This Year
The growth prospects for these two businesses should improve as they become leaner. 
Via The Motley Fool
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
 
Via Benzinga
3 Dow Stocks Near 52-Week Lows That Look Like Bargains Now
These businesses are performing much better than their stock prices would suggest. 
Via The Motley Fool
Top 8 Stocks To Profit From Rising Interest Rates
The US Federal Reserve raises interest rates when the market is growing too fast, which is what has been happening over the past year. Here are some stocks to help you answer the question of how to... 
Via Talk Markets
3 Retirement Investing Moves to Help Get You Back on Track
If you've fallen behind on funding your retirement, it's important to do what you can to get yourself on a path to recovery. 
Via The Motley Fool
5 Stocks You Can Confidently Invest $500 in Right Now
These companies have the balance sheets and growth prospects to continue growing shareholder value in the coming years. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
It's still unclear whether CMS will include those drugs in its negotiation list. 
Via Investor's Business Daily
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies
 
Via Benzinga
7 Blue-Chip Stocks to Buy and Hold for Decades
For steady returns via growing dividends and gradual price appreciation, consider these seven blue-chip stocks to buy and hold. 
Via InvestorPlace
Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature
From Johnson & Johnson
Via Business Wire
3 Blue-Chip Dividend Stocks to Buy on the Dip Now
In times of uncertainty, investors want companies they can count on. Let's look at a few of the best blue-chip dividend stocks to buy. 
Via InvestorPlace
Healthcare Stocks With at Least 30 Years of Dividend Increases
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. 
Via MarketBeat
5 Forever Dividend Stocks
These five dividend stocks make it a priority to return money to shareholders. 
Via The Motley Fool
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.